Business Description
Biocytogen Pharmaceuticals is a Beijing-based biotechnology company founded in 2008 that develops antibody-based drugs and offers preclinical research services across China, the United States, and other markets. The company runs a broad range of operations, from custom gene editing and animal model breeding to antibody discovery and drug candidate development, with a particular focus on cancer and autoimmune diseases. Its leading drug candidates include YH001, used to treat advanced solid tumors, and YH002, currently in Phase I clinical trials. The company works alongside several partners, including Syncromune Inc., RemeGen Co., and Chipscreen NewWay Biosciences.
